Literature DB >> 1581116

Outcome variables in osteoporosis trials.

M Kleerekoper1, D A Nelson, E L Peterson, B C Tilley.   

Abstract

The conduct of controlled clinical trials examining the anti-fracture efficacy of potential therapies for osteoporosis is a relatively new and developing science. We have reviewed several aspects of data acquisition, emphasizing that bone mass measurement and, similarly, back pain can only be regarded as ancillary outcome variables. Serial measurement of stature when performed in a precise manner may be an inexpensive, quick, and convenient surrogate outcome variable, most applicable to large multi-center studies. The only true end-point of such trials is the radiographic documentation of new vertebral fracture occurrence. Techniques for obtaining serial radiographs and assessing vertebral morphometry with good quality control have been described. Important questions still need to be resolved concerning the most appropriate criteria for defining incident fractures and for calculating fracture frequency. Implications regarding trial sample size requirements are discussed.

Entities:  

Mesh:

Year:  1992        PMID: 1581116     DOI: 10.1016/s8756-3282(09)80007-0

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  13 in total

1.  Detective value of historical height loss and current height/knee height ratio for prevalent vertebral fracture in Japanese postmenopausal women.

Authors:  Kousei Yoh; Akiko Kuwabara; Kiyoshi Tanaka
Journal:  J Bone Miner Metab       Date:  2014-09       Impact factor: 2.626

2.  The accuracy of historical height loss for the detection of vertebral fractures in postmenopausal women.

Authors:  K Siminoski; R S Warshawski; H Jen; K Lee
Journal:  Osteoporos Int       Date:  2005-09-06       Impact factor: 4.507

3.  Skin color and body size as risk factors for osteoporosis.

Authors:  D A Nelson; M Kleerekoper; E Peterson; A M Parfitt
Journal:  Osteoporos Int       Date:  1993-01       Impact factor: 4.507

4.  Bone mineral density and estimated height loss based on patients' recalls.

Authors:  A Moayyeri; S Ahmadi-Abhari; A Hossein-nezhad; B Larijani; A Soltani
Journal:  Osteoporos Int       Date:  2006-03-31       Impact factor: 4.507

5.  A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica.

Authors:  J H Healey; S A Paget; P Williams-Russo; T P Szatrowski; R Schneider; H Spiera; H Mitnick; K Ales; P Schwartzberg
Journal:  Calcif Tissue Int       Date:  1996-02       Impact factor: 4.333

6.  Comparison of semiquantitative and quantitative techniques for the assessment of prevalent and incident vertebral fractures.

Authors:  C Y Wu; J Li; M Jergas; H K Genant
Journal:  Osteoporos Int       Date:  1995       Impact factor: 4.507

7.  Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study.

Authors:  H Rico; M Revilla; E R Hernández; L F Villa; M Alvarez de Buergo
Journal:  Calcif Tissue Int       Date:  1995-03       Impact factor: 4.333

8.  Measurement of height: practical considerations for the study of osteoporosis.

Authors:  R J Coles; D G Clements; W D Evans
Journal:  Osteoporos Int       Date:  1994-11       Impact factor: 4.507

9.  The association between higher serum ferritin level and lower bone mineral density is prominent in women ≥45 years of age (KNHANES 2008-2010).

Authors:  B-J Kim; S H Lee; J-M Koh; G S Kim
Journal:  Osteoporos Int       Date:  2013-04-17       Impact factor: 4.507

10.  Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures.

Authors:  K Siminoski; G Jiang; J D Adachi; D A Hanley; G Cline; G Ioannidis; A Hodsman; R G Josse; D Kendler; W P Olszynski; L-G Ste Marie; R Eastell
Journal:  Osteoporos Int       Date:  2004-08-11       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.